TNBC represents a significant clinical challenge in the landscape of breast cancer due to its unique molecular profile characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression [4,5]. This evidence concerns the gene ERBB2 and breast cancer.